Travere Therapeutics, Inc.
Travere Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on October 17, 2026, a projected date rather than a confirmed one. There are 6 upcoming events on record.
Cash runway is approximately 21.8 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 9 concluded trials, 89% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| October 17, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| March 12, 2027 | Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases | Trial Milestone | Phase 2 |
| March 15, 2027 | Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis | Trial Milestone | Phase 4 |
| July 15, 2027 | Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study) | Trial Milestone | Phase 1/Phase 2 |
| August 15, 2027 | Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment | Trial Milestone | Phase 3 |
| August 15, 2030 | A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) | Trial Milestone | Phase 3 |
Track TVTX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open TVTX in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.